StockMarketWire.com - Scancell said active patient enrollment for a clinical trial of a cancer treatment was expected to begin in the coming weeks.

The company had in April announced that it had received the necessary regulatory and ethical approvals to initiate the UK arm of the so-called SCIB1 trial.

Operational activities for clinical centre initiation had since been completed.


At 9:50am: [LON:SCLP] Scancell Holdings PLC share price was +0.1p at 6.85p



Story provided by StockMarketWire.com